Studies have shown that most of the Dual PPARα/γ agonist play an active role in anti-atherosclerosis, such as GQ-11 (Silva, 2018), P633H (Chen et al., 2009), C333H (Xu et al., 2006), LT175 (Gilardi et al., 2014), and Tesaglitazar (Zadelaar et al., 2006; Chira et al., 2007; Table 1). Here, PPARA is linked to atherosclerosis.